drugset / Trial / NCT06555822

A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

NCT06555822

Phase 1 Completed 31 enrolled AstraZeneca
RandomizedParallel-groupSingle-blindTreatment

Summary

The main purpose of this study is to assess the safety, tolerability, and pharmacokinetic (PK) of AZD5004 administered as multiple oral doses in healthy participants and to compare the relative bioavailability of two oral tablet strengths of AZD5004.

Timeline

Start
2024-08-15
Primary completion
2025-03-06
Completion
2025-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD5004 Unknown Oral

Indications

No indication recorded.